Acanthosis nigricans in obese patients: Presentations and implications for prevention of atherosclerotic vascular disease;Acantosis nigricans en pacientes obesos: Formas de presentación e implicaciones para la prevención de la enfermedad vascular aterosclerótica

Dermatology Online Journal

Volumn 6, Issue 1, 2000, Pages 1-24

  Katz, Aaron S ^a   Goff, David C ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; INSULIN; KERATOLYTIC AGENT; RETINOID;

ACANTHOSIS NIGRICANS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIET; DISEASE ASSOCIATION; DISEASE SEVERITY; EPIDERMIS; EXERCISE; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERKERATOSIS; HYPERPIGMENTATION; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; POPULATION; RISK ASSESSMENT; RISK REDUCTION; SKINFOLD; SYMPTOM; VASCULAR DISEASE; ARTERIOSCLEROSIS;

ACANTHOSIS NIGRICANS; ARTERIOSCLEROSIS; HUMANS; INSULIN RESISTANCE; OBESITY;

EID: 0034279987     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol 1994;31(1):1-19; quiz 20-2. PubMed
2. Davidson MB. Clinical implications of insulin resistance syndromes [see comments] Am J Med 1995;99(4):420-6. PubMed
3. Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications New England Journal of Medicine, 1991 Sep 26, 325(13):938-48. PubMed
4. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. Journal of Investigative Dermatology, 1992 Jun, 98(6 Suppl):82S-85S. PubMed
5. Mei Z, Scanlon KS, Grummer-Strawn LM, Freedman DS, Yip R, Trowbridge FL. Increasing prevalence of overweight among US low-income preschool children: the Centers for Disease Control and Prevention pediatric nutrition surveillance, 1983 to 1995. Pediatrics, 1998 Jan, 101(1):E12. PubMed
6. Heini AF, Weinsier RL. Divergent trends in obesity and fat intake patterns: the American paradox. Am J Med 1997;102(3):259-64. PubMed
7. Stuart CA, Gilkison CR, Smith MM, Bosma AM, Keenan BS, Nagamani M. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clinical Pediatrics, 1998 Feb, 37(2):73-9. PubMed
8. Flier JS. Metabolic importance of acanthosis nigricans [editorial] Arch Dermatol 1985;121(2):193-4. PubMed
9. Stuart CA, Gilkison CR, Keenan BS, Nagamani M. Hyperinsulinemia and acanthosis nigricans in African Americans [see comments] J Natl Med Assoc 1997;89(8):523-7. PubMed
10. Schwartz RA, Janniger CK. Childhood acanthosis nigricans. Cutis 1995;55(6):337-41. PubMed
11. Azizi E, Trau H, Schewach-Millet M, Rosenberg V, Schneebaum S, Michalevicz R. Generalized malignant acanthosis nigricans [letter]. Archives of Dermatology, 1980 Apr, 116(4):381. PubMed
12. Hazen PG, Carney JF, Walker AE, Stewart JJ. Acanthosis nigricans presenting as hyperkeratosis of the palms and soles. J Am Acad Dermatol 1979;1(6):541-4. PubMed
13. Howard G, Bergman R, Wagenknecht LE, Haffner SM, Savage PJ, Saad MF, Laws A, D'Agostino RB Jr. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model". Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol 1998;8(6):358-69. PubMed
14. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37(12):1595-607. PubMed
15. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention [published erratum appears in JAMA 1999 Jan 27;281(4):325] [see comments] JAMA 1998;280(20):1757-63. PubMed
16. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention [published erratum appears in JAMA 1999 Jan 27;281(4):325] [see comments] JAMA 1998;280(20):1757-63. PubMed
17. Laakso M. Insulin resistance and coronary heart disease. Current Opinion in Lipidology, 1996 Aug, 7(4):217-26. PubMed
18. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Annals of Internal Medicine, 1996 Jan 1, 124(1 Pt 2):110-6. PubMed
19. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2(2):154-60. PubMed
20. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkanen L, Selby J, Howard G, Savage PJ, Hamman RF, Wagenknecht LE, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996;45(6):742-8. PubMed
21. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators [see comments]. Circulation, 1996 May 15, 93(10):1809-17. PubMed
22. Field JB, Johnson P, Herring B: Insulin-resistant diabetes associated with increased endogenous plasma insulin followed by complete remission. J Clin Invest 1961;40:1672-1683.
23. Bar RS, Harrison LC, Muggeo M, Gorden P, Kahn CR, Roth J. Regulation of insulin receptors in normal and abnormal physiology in humans. Advances in Internal Medicine, 1979, 24:23-52. PubMed